Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Enanta Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Enanta Pharmaceuticals's total assets was $275.58M at Sep 30, 2026. For fiscal 2026 it was $275.58M, down 1.8% from the year before. Over ten years it grew -0.2% a year on average. The highest annual figure on record is $489.83M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | $275.58M | -1.8% |
| FY2025 | Sep 30, 2025 | $280.73M | -25.5% |
| FY2024 | Sep 30, 2024 | $376.65M | -18.5% |
| FY2023 | Sep 30, 2023 | $462.28M | +23.1% |
| FY2022 | Sep 30, 2022 | $375.41M | -14.4% |
| FY2021 | Sep 30, 2021 | $438.79M | -9.7% |
| FY2020 | Sep 30, 2020 | $486.13M | -0.8% |
| FY2019 | Sep 30, 2019 | $489.83M | +18.3% |
| FY2018 | Sep 30, 2018 | $414.23M | +26.8% |
| FY2017 | Sep 30, 2017 | $326.64M | +16.1% |
| FY2016 | Sep 30, 2016 | $281.28M | +14.3% |
| FY2015 | Sep 30, 2015 | $246.01M | +58.3% |
| FY2014 | Sep 30, 2014 | $155.42M | +32.9% |
| FY2013 | Sep 30, 2013 | $116.97M | +124.2% |
| FY2012 | Sep 30, 2012 | $52.16M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | $275.58M | -1.8% |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $296.87M | -1.4% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $314.70M | -9.7% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $329.50M | -12.5% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $280.73M | -29.6% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $301.03M | -27.2% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $348.64M | -18.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $376.65M | -18.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $398.82M | -19.5% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $413.56M | +26.7% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $428.50M | +23.3% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $462.28M | +23.1% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $495.17M | +28.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $326.45M | -19.8% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $347.53M | -21.1% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $375.41M | -14.4% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $385.21M | -14.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $406.82M | -13.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $440.59M | -8.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $438.79M | -9.7% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $450.44M | -12.0% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $467.77M | -8.9% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $481.01M | -5.9% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $486.13M | -0.8% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $511.70M | +8.1% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $513.50M | +11.2% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $510.97M | +12.5% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $489.83M | +18.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $473.48M | +24.9% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $461.58M | +30.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $454.22M | +33.3% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $414.23M | +26.8% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $379.09M | +37.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $354.65M | +27.1% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $340.72M | +22.4% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $326.64M | +16.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $275.84M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $278.96M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $278.38M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $281.28M | – |
See a number that looks wrong?